Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial
Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial
复制标题
分化型甲状腺癌患者的放射性碘摄取和甲状腺球蛋白引导的放射性碘残留消融：一项前瞻性、随机、开放标签、对照试验
DOI：
10.1089/thy.2018.0028
复制
发表时间：
2019-01-01
期刊：
影响因子：
6.6
通讯作者：
Chen, Libo
中科院分区：
文献类型：
--
作者：
Jin, Yuchen;Ruan, Maomei;Chen, Libo
背景：放射性碘（I-131）残余消融（RRA）已成为分化型甲状腺癌（DTC）术后治疗的关键步骤。然而，在固定活动中，I-131不足或过量是常见的。本研究旨在探讨放射性碘摄取和甲状腺球蛋白（RAIU-Tg）引导RRA的可行性。方法：将277例患者按4:1的比例随机分为基于raiu - tg的活动组和固定3.7 GBq的活动组。以4个水平的RAIU（15%）和Tg （10 ng/mL）为基础，建立了基于RAIU-Tg的活性。在此基础上，I-131活性分别为1.1、1.85、3.7和5.55 GBq。如果RAIU和Tg的水平不在同一类别，则给予由RAIU或Tg确定的较高活动。成功的RRA定义为诊断性全身扫描和Tg阴性
Background: Radioiodine (I-131) remnant ablation (RRA) has become a key step in the postoperative treatment of differentiated thyroid cancer (DTC). However, inadequate or excessive I-131 is common using fixed activities. This study was designed to explore the feasibility of radioiodine uptake and thyroglobulin (RAIU-Tg)-guided RRA. Methods: A total of 277 patients were randomized to the RAIU-Tg-based activity group or a fixed activity of 3.7 GBq group at a ratio of 4:1. The RAIU-Tg-based activity was established based on four levels of RAIU (15%) and Tg levels (10 ng/mL). Based on this, I-131 activities of 1.1, 1.85, 3.7, and 5.55 GBq were administered. If the levels for RAIU and Tg were not in the same category, the higher activity determined by either RAIU or Tg was administered. Successful RRA was defined as negative diagnostic whole-body scan and Tg